Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
Identifieur interne : 001C02 ( Main/Exploration ); précédent : 001C01; suivant : 001C03Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
Auteurs : Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-07-30.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Amantadine, Amantadine (therapeutic use), Antiparkinson Agents (therapeutic use), Double-Blind Method, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Humans, Levodopa (adverse effects), Long term, Longitudinal Studies, Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Treatment Outcome, amantadine, dyskinesia.
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Middle Aged, Severity of Illness Index, Treatment Outcome.
Abstract
Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23034
Affiliations:
- Autriche
- Tyrol (Land), Vienne (Autriche)
- Innsbruck, Vienne (Autriche)
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F00
- to stream Istex, to step Curation: 000F00
- to stream Istex, to step Checkpoint: 000881
- to stream PubMed, to step Corpus: 001919
- to stream PubMed, to step Curation: 001919
- to stream PubMed, to step Checkpoint: 001800
- to stream Ncbi, to step Merge: 002A83
- to stream Ncbi, to step Curation: 002A83
- to stream Ncbi, to step Checkpoint: 002A83
- to stream Main, to step Merge: 002038
- to stream PascalFrancis, to step Corpus: 000A05
- to stream PascalFrancis, to step Curation: 002314
- to stream PascalFrancis, to step Checkpoint: 000985
- to stream Main, to step Merge: 002572
- to stream Main, to step Curation: 001C02
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name>
</author>
<author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name>
</author>
<author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name>
</author>
<author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name>
</author>
<author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name>
</author>
<author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name>
</author>
<author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1C9A66976BC562F924CA6A7316825E57141144AE</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23034</idno>
<idno type="url">https://api.istex.fr/document/1C9A66976BC562F924CA6A7316825E57141144AE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F00</idno>
<idno type="wicri:Area/Istex/Curation">000F00</idno>
<idno type="wicri:Area/Istex/Checkpoint">000881</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Wolf E:long:term:antidyskinetic</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20198649</idno>
<idno type="wicri:Area/PubMed/Corpus">001919</idno>
<idno type="wicri:Area/PubMed/Curation">001919</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001800</idno>
<idno type="wicri:Area/Ncbi/Merge">002A83</idno>
<idno type="wicri:Area/Ncbi/Curation">002A83</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002A83</idno>
<idno type="wicri:Area/Main/Merge">002038</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0377327</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A05</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002314</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000985</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Wolf E:long:term:antidyskinetic</idno>
<idno type="wicri:Area/Main/Merge">002572</idno>
<idno type="wicri:Area/Main/Curation">001C02</idno>
<idno type="wicri:Area/Main/Exploration">001C02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease</title>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Sozialmedizinisches Zentrum Ost, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Neurological Center Rosenhügel, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, General Hospital Linz, Linz</wicri:regionArea>
<wicri:noRegion>Linz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Graz, Graz</wicri:regionArea>
<wicri:noRegion>Graz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Graz, Graz</wicri:regionArea>
<wicri:noRegion>Graz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Barmherzige Brüder Graz, Graz</wicri:regionArea>
<wicri:noRegion>Graz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University of Vienna, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-07-30">2010-07-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1357">1357</biblScope>
<biblScope unit="page" to="1363">1363</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1C9A66976BC562F924CA6A7316825E57141144AE</idno>
<idno type="DOI">10.1002/mds.23034</idno>
<idno type="ArticleID">MDS23034</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Amantadine</term>
<term>Amantadine (therapeutic use)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Long term</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
<term>amantadine</term>
<term>dyskinesia</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term>
<term>Dyskinésie</term>
<term>Long terme</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo‐controlled parallel‐group study was performed to assess the long‐term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year‐ were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1–4.03) at baseline to 4.28 (95% CI, 3.1–5.4) at three‐week follow‐up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1–4.4) to follow‐up 3.6 (95% CI, 2.3–4.8) in patients staying on amantadine. These findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
<li>Vienne (Autriche)</li>
</region>
<settlement><li>Innsbruck</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
</noRegion>
<name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name>
<name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name>
<name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name>
<name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name>
<name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name>
<name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name>
<name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:1C9A66976BC562F924CA6A7316825E57141144AE |texte= Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |